Everest Medicines announced that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (Everest Medicines China), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (Hasten). The first is a Commercialisation Services Agreement leveraging Everest's existing sales and marketing organisation to provide commercialisation services for a portfolio of Hasten's mature assets.
The second is a License Agreement granting Everest the exclusive license to develop, register and commercialise Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China.
The two agreements are expected to create significant financial and strategic synergies, enhancing the operational efficiency of Everest’s existing commercial platform and accelerating the build-out of life-cycle and multi-channel commercialisation capabilities. At the same time, they establish an attractive strategic footprint for the Company in the cardiovascular disease area. Through this collaboration, Everest will further strengthen its commercial foundation in China, expand market share, and inject core momentum into the long-term growth of its cardiovascular business. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest's cardiovascular portfolio.
Everest Medicines China will receive service fees from Hasten calculated by multiplying the net sales of each product for the applicable quarter by the applicable rate, which ranges from 20 per cent to 55 per cent. The proposed maximum annual caps for the transactions contemplated to be paid by Hasten for the three years ending December 31, 2028, are set at RMB 560 million in 2026, RMB 616 million in 2027, and RMB 677 million in 2028.
The Commercialisation Service Agreement covers six mature, commercially available products across three major therapeutic areas—critical care, cardiovascular disease, and metabolic disorders—including Rocephin(R), Stilamin(R), and Ebrantil(R) in critical care; Edarbi(R) and Blopress(R) in cardiovascular disease; and Basen(R) in metabolic disease. The portfolio is highly synergistic with Everest’s existing commercial infrastructure and strategic focus. Among them, the three core critical care products—Rocephin(R), Stilamin(R), and Ebrantil(R)—play an essential clinical role in the treatment of infectious, gastrointestinal, and cardiovascular emergency conditions.
